Skip to content

Metabolic & GLP-1 · Reference monograph

Dual GLP-1 and glucagon receptor agonist

Reference compound — not available from Purity Peptides. Shown for research context.

Overview

Survodutide is an investigational dual agonist of the glucagon and GLP-1 receptors developed by Boehringer Ingelheim in collaboration with Zealand Pharma. It is an acylated peptide with a long half-life suitable for once-weekly regimens in clinical trials, and its design reflects the hypothesis that adding glucagon-receptor activity to GLP-1 agonism can increase energy expenditure and directly reduce liver fat.

A phase 2 trial in people with metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis, published in 2024, reported improvement in MASH without worsening fibrosis in a large majority of participants receiving the compound. Phase 2 obesity studies also reported meaningful weight reductions. Phase 3 programmes in obesity (SYNCHRONIZE) and MASH are ongoing. Survodutide is not approved anywhere. Our product is a research-grade reference compound for studies of hepatic metabolism and dual-receptor pharmacology.

Mechanism studied

  1. Survodutide
  2. GLP-1R + GCGR
  3. Hepatic lipid oxidation
  4. Liver & weight endpoints

Survodutide activates the glucagon receptor, abundant in the liver, and the GLP-1 receptor, found in the pancreas, gut and brain. Hepatic glucagon-receptor signalling increases fatty-acid oxidation and reduces lipogenesis, lowering liver fat, and may raise energy expenditure. GLP-1 receptor signalling reduces appetite, slows gastric emptying and enhances glucose-dependent insulin release, offsetting the glucose-raising potential of glucagon agonism. The relative balance between the two activities is a key design parameter studied across this drug class.

Research highlights

  • 01Dual glucagon and GLP-1 receptor agonist from Boehringer Ingelheim and Zealand
  • 02Phase 2 MASH trial published in the New England Journal of Medicine (2024)
  • 03Glucagon-receptor activity targets hepatic lipid metabolism
  • 04Phase 3 programmes in obesity and MASH are ongoing
  • 05Not approved by any regulator

Latest published research

93 papers on PubMed →

  1. Interpreting Survodutide Renoprotection in a Hyperfiltration Model

    Ye T et al. · Diabetes, obesity & metabolism · 2026 Oct 19 · PMID 42897119

  2. From pathophysiology to therapy: dual and triple agonists as a new frontier in metabolic dysfunction-associated steatotic liver disease

    Argano C et al. · Frontiers in pharmacology · 2026 · PMID 42947668

  3. Does Survodutide Provide Renoprotection Beyond Its Metabolic and Haemodynamic Effects in Diabetic Kidney Disease?

    He J et al. · Diabetes, obesity & metabolism · 2026 Oct 12 · PMID 42864267

  4. The Power of Two: Harnessing Dual Glucagon and Incretin Signaling for Treatment of Obesity and Metabolic Dysfunction-Associated Steatohepatitis-A Narrative Review with a Translational Focus

    Ard JD et al. · Obesity reviews : an official journal of the International Association for the Study of Obesity · 2026 Oct 11 · PMID 42860310

  5. Development and validation of a multiplexed LC-HRMS method for nine GLP-1 receptor agonists and its pharmaceutical application

    Tong LH et al. · Journal of chromatography. A · 2026 Oct 11 · PMID 42603384

  6. Survodutide for the treatment of obesity: Mechanistic rationale, clinical evidence, and remaining uncertainties

    Sergi CM et al. · Contemporary clinical trials · 2026 Oct 2 · PMID 42822760

  7. Nephroprotective Effects of the Dual GCGR/GLP-1R Agonist Survodutide in Hypertension-Accelerated Diabetic Kidney Disease

    Hamilton A et al. · Diabetes, obesity & metabolism · 2026 Oct 1 · PMID 42823075

  8. Survodutide Once Weekly in Adults with Obesity and Type 2 Diabetes

    Wharton S et al. · The New England journal of medicine · 2026 Oct 1 · PMID 42820639

Live feed from PubMed (NCBI) for “Survodutide”, updated 2026-10-30. Listing a paper is not an endorsement of its findings.

Registered studies

29 on ClinicalTrials.gov →

From the public ClinicalTrials.gov registry for “Survodutide”, updated 2026-10-30. Shown for research context only; Purity Peptides products are not for human use.

Key references

  1. [1]Sanyal et al., 2024 — N Engl J Med (MASH)
  2. [2]PubMed — reviews on survodutide

FAQ

  • Glucagon receptors are highly expressed in the liver, and activating them increases fat oxidation in hepatocytes. Combining this with GLP-1 agonism has made survodutide a candidate in MASH research, where reductions in liver fat and inflammation are key endpoints in clinical and preclinical studies.

  • Lyophilized Survodutide is normally kept sealed at −20 °C, protected from light and moisture. Once reconstituted for laboratory work, aliquots are held at 2–8 °C for short-term use or frozen, avoiding repeated freeze–thaw. Follow the lot-specific guidance on the certificate of analysis.

  • Every lot of Survodutide ships with a certificate of analysis reporting HPLC purity, mass-spectrometry identity against the expected molecular weight, appearance and lot number. Match the COA lot to the vial label and keep it with your experimental records.

FOR RESEARCH USE ONLY.Not for human or veterinary use. Not intended to diagnose, treat, cure, or prevent any disease.

Related compounds

WhatsApp